Value Not Disclosed | Novo Holdings (logo) has agreed to acquire a majority stake in Single Use Support (logo) | Pending

William Blair acted as the exclusive financial advisor to Novo Holdings in connection with its pending majority stake acquisition of Single Use Support. The transaction was announced on May 15, 2024, with closing expected later in Q2 2024. This transaction continues William Blair’s European buyside momentum: the 11th transaction in the last 12 months representing roughly EUR 7.5 billion in cumulative transaction value.

About the Companies

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of the company is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, Asia, Bioindustrial and Principal Investments teams, the company invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.

Single Use Support is a pioneering process solution provider specializing in fluid and cold chain management of drug substances. The company focuses on the development of solutions to provide manufacturers with 100 percent safe and efficient handling, liquid transfer, freezing and cold chain shipping of advanced therapies and biologics in pharmaceutical production. Founded in 2017, the company made its way to a highly respected innovation leader in a fast-growing market and serves customers globally. Single Use Support is based in Kufstein/Austria and operates from a US subsidiary in Lexington MA. Roughly 200 associates globally ensure that innovation continuous and products and services simplify the life of global biopharma and advanced therapies clients.

Learn more about our medical technology investment banking expertise.